Di Vincenzo, A. http://orcid.org/0000-0002-7678-5671
Crescenzi, M.
Granzotto, M.
Vecchiato, M.
Fioretto, P.
Vettor, R.
Rossato, M.
Funding for this research was provided by:
AstraZeneca (476/2016)
Article History
Received: 19 July 2023
Accepted: 5 December 2023
First Online: 9 January 2024
Declarations
:
: P.F. is involved as advisory board member and speaker for AstraZeneca, Eli Lilly, Boehringer Ingelheim, Novo, and Bayer.
: As reported in the Methods section, the procedures involving animal care followed institutional guidelines that comply with national and international laws and policies (European Economic Community Council Directive 86/609, OJ L 358, 1 Dec.2012, 1987; NIH Guide for the Care and Use of Laboratory Animals, NIH Publication no. 85–23, 1985). The study design was approved by the Ethics Committee of the University of Padova for the care and use of laboratory animals (CEASA protocol number 58/2018-PR, approved by the Ethics Committee of the University of Padova, Italy). All experiments followed committee guidelines and the institutional protocol for animal care that was approved by the Italian Ministry of Health (58/2018-PR).
: Not applicable.
: For this type of study, consent is not required.